Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 13, 4042-4045, July 15, 2007. doi: 10.1158/1078-0432.CCR-06-2316
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katoh, M.
Right arrow Articles by Katoh, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katoh, M.
Right arrow Articles by Katoh, M.

Molecular Pathways

WNT Signaling Pathway and Stem Cell Signaling Network

Masuko Katoh1 and Masaru Katoh2

Authors' Affiliations: 1 M&M Medical BioInformatics, Hongo, Japan and 2 Genetics and Cell Biology Section, National Cancer Center Research Institute, Tokyo, Japan

Requests for reprints: Masaru Katoh, Genetics and Cell Biology Section, National Cancer Center Research Institute, 5-1-1 Tsukiji, Tokyo 104-0045, Japan. Phone: 81-3-3542-2511; Fax: 81-3-3541-2685; E-mail: mkatoh-kkr{at}umin.ac.jp.

Abstract

WNT signals are transduced to the canonical pathway for cell fate determination, and to the noncanonical pathway for control of cell movement and tissue polarity. Canonical WNT signals are transduced through Frizzled family receptors and LRP5/LRP6 coreceptor to the ß-catenin signaling cascade. Microtubule affinity–regulating kinase (PAR-1) family kinases, casein kinase I{varepsilon} (CKI{varepsilon}), and FRAT are positive regulators of the canonical WNT pathway, whereas APC, AXIN1, AXIN2, CKI{alpha}, NKD1, NKD2, ßTRCP1, ßTRCP2, ANKRD6, Nemo-like kinase (NLK), and peroxisome proliferator–activated receptor {gamma} (PPAR{gamma}) are negative regulators. Nuclear complex, consisting of T-cell factor/lymphoid enhancer factor, ß-catenin, BCL9/BCL9L, and PYGO, activates transcription of canonical WNT target genes such as FGF20, DKK1, WISP1, MYC, CCND1, and Glucagon (GCG). Noncanonical WNT signals are transduced through Frizzled family receptors and ROR2/RYK coreceptors to the Dishevelled-dependent (Rho family GTPases and c-jun NH2-terminal kinase) or the Ca2+-dependent (NLK and nuclear factor of activated T cells) signaling cascades. WNT signals are context-dependently transduced to both pathways based on the expression profile of WNT, SFRP, WIF, DKK, Frizzled receptors, coreceptors, and the activity of intracellular WNT signaling regulators. Epigenetic silencing and loss-of-function mutation of negative regulators of the canonical WNT pathway occur in a variety of human cancer. WNT, fibroblast growth factor (FGF), Notch, Hedgehog, and transforming growth factor ß/bone morphogenetic protein signaling network are implicated in the maintenance of tissue homeostasis by regulating self-renewal of normal stem cells as well as proliferation or differentiation of progenitor (transit-amplifying) cells. Breakage of the stem cell signaling network leads to carcinogenesis. Nonsteroidal anti-inflammatory drugs and PPAR{gamma} agonists with the potential to inhibit the canonical WNT signaling pathway are candidate agents for chemoprevention. ZTM000990 and PKF118-310 are lead compounds targeted to the canonical WNT signaling cascade. Anti-WNT1 and anti-WNT2 monoclonal antibodies show in vitro effects in cancer treatment. After the optimization, derivatives of small-molecule compound and human monoclonal antibody targeted to the WNT signaling pathway could be used in cancer medicine.




This article has been cited by other articles:


Home page
J. Immunol.Home page
S. Malhotra, Y. Baba, K. P. Garrett, F. J. T. Staal, R. Gerstein, and P. W. Kincade
Contrasting Responses of Lymphoid Progenitors to Canonical and Noncanonical Wnt Signals
J. Immunol., September 15, 2008; 181(6): 3955 - 3964.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Doghman, J. Cazareth, and E. Lalli
The T cell factor/{beta}-Catenin Antagonist PKF115-584 Inhibits Proliferation of Adrenocortical Carcinoma Cells
J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 3222 - 3225.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. E.P. Prince and L. E. Ailles
Cancer Stem Cells in Head and Neck Squamous Cell Cancer
J. Clin. Oncol., June 10, 2008; 26(17): 2871 - 2875.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
L Ricci-Vitiani, A Pagliuca, E Palio, A Zeuner, and R De Maria
Colon cancer stem cells
Gut, April 1, 2008; 57(4): 538 - 548.
[Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
X.-Z. Wu
Origin of Cancer Stem Cells: The Role of Self-Renewal and Differentiation
Ann. Surg. Oncol., February 1, 2008; 15(2): 407 - 414.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.